- Home
- STM vs DGX Comparison
STM vs DGX Comparison
Compare STM & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STM
- DGX
- Stock Information
- Founded
- STM 1987
- DGX 1967
- Country
- STM Netherlands
- DGX United States
- Employees
- STM N/A
- DGX N/A
- Industry
- STM Semiconductors
- DGX Medical Specialities
- Sector
- STM Technology
- DGX Health Care
- Exchange
- STM Nasdaq
- DGX Nasdaq
- Market Cap
- STM 22.3B
- DGX 19.8B
- IPO Year
- STM 1994
- DGX 1996
- Fundamental
- Price
- STM $28.67
- DGX $179.43
- Analyst Decision
- STM Buy
- DGX Buy
- Analyst Count
- STM 8
- DGX 14
- Target Price
- STM $32.00
- DGX $185.07
- AVG Volume (30 Days)
- STM 7.5M
- DGX 805.2K
- Earning Date
- STM 07-24-2025
- DGX 07-22-2025
- Dividend Yield
- STM 1.07%
- DGX 1.78%
- EPS Growth
- STM N/A
- DGX 6.41
- EPS
- STM 1.18
- DGX 7.91
- Revenue
- STM $12,321,000,000.00
- DGX $10,158,000,000.00
- Revenue This Year
- STM N/A
- DGX $10.38
- Revenue Next Year
- STM $14.19
- DGX $4.03
- P/E Ratio
- STM $23.16
- DGX $22.67
- Revenue Growth
- STM N/A
- DGX 9.38
- 52 Week Low
- STM $17.25
- DGX $135.47
- 52 Week High
- STM $43.32
- DGX $182.38
- Technical
- Relative Strength Index (RSI)
- STM 59.74
- DGX 58.65
- Support Level
- STM $29.11
- DGX $177.76
- Resistance Level
- STM $29.82
- DGX $182.38
- Average True Range (ATR)
- STM 0.71
- DGX 2.85
- MACD
- STM -0.07
- DGX 0.45
- Stochastic Oscillator
- STM 68.38
- DGX 73.96
About STM STMicroelectronics N.V.
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.